Totally agree, and reading the transcript of Bausch 's conference it's easy to realise that BOT would be perfectly positioned for acquisition on positive trial's results in that it'll have an eyes watering product pipeline, ripe and ready for inclusion in their R&D portfolio.
Bot Chart, page-245
-
- There are more pages in this discussion • 1,281 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.5¢ | $1.940M | 6.061M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 470483 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 33000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |